Fintel reports that on September 22, 2023, HC Wainwright & Co. reiterated coverage of Entrada Therapeutics (NASDAQ:TRDA) with a Buy recommendation.
Analyst Price Forecast Suggests 61.13% Upside
As of August 31, 2023, the average one-year price target for Entrada Therapeutics is 21.93. The forecasts range from a low of 18.18 to a high of $26.25. The average price target represents an increase of 61.13% from its latest reported closing price of 13.61.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Entrada Therapeutics is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -3.90.
What is the Fund Sentiment?
There are 138 funds or institutions reporting positions in Entrada Therapeutics. This is an increase of 46 owner(s) or 50.00% in the last quarter. Average portfolio weight of all funds dedicated to TRDA is 0.83%, an increase of 46.01%. Total shares owned by institutions increased in the last three months by 4.22% to 26,005K shares.
What are Other Shareholders Doing?
Baker Bros. Advisors holds 4,866K shares representing 14.64% ownership of the company. No change in the last quarter.
Mpm Asset Management holds 4,426K shares representing 13.32% ownership of the company. No change in the last quarter.
5AM Venture Management holds 4,408K shares representing 13.26% ownership of the company. No change in the last quarter.
Price T Rowe Associates holds 2,938K shares representing 8.84% ownership of the company. In it's prior filing, the firm reported owning 2,984K shares, representing a decrease of 1.55%. The firm increased its portfolio allocation in TRDA by 115.93% over the last quarter.
PRNHX - T. Rowe Price New Horizons Fund holds 1,783K shares representing 5.36% ownership of the company. In it's prior filing, the firm reported owning 1,784K shares, representing a decrease of 0.03%. The firm decreased its portfolio allocation in TRDA by 1.01% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
